These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24493578)

  • 1. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
    Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
    Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Utilization Patterns and Costs of Erythropoiesis-Stimulating Agents in an Outpatient Setting in Greece.
    Papachristos A; Kani C; Litsa P; Valsami G; Souliotis K; Saridi M; Markantonis S
    Consult Pharm; 2016 May; 31(5):271-81. PubMed ID: 27178657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and costs of originator and biosimilar erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia: real-world evidence from an Italian hospital.
    Santoleri F; Romagnoli A; Costantini A
    Future Oncol; 2019 Jan; 15(1):45-51. PubMed ID: 30468397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
    Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
    BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
    Ingrasciotta Y; Sultana J; Formica D; Ientile V; Aiello A; Chinellato A; Tari DU; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Rossi M; Santoro D; Trifirò G;
    Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):65-77. PubMed ID: 33067914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
    Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
    Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries.
    Abraham I; Han L; Sun D; MacDonald K; Aapro M
    Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective.
    Gauthier-Loiselle M; Michalopoulos SN; Cloutier M; Serra E; Bungay R; Szabo E; Guérin A
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1703-1713. PubMed ID: 34818094
    [No Abstract]   [Full Text] [Related]  

  • 14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011.
    Loiacono C; Sgroi C; Coppolino S; Cannata A; Ferrara R; Arcoraci V; Cananzi P; Savica V; Schuemie M; Caputi AP; Trifirò G
    BioDrugs; 2012 Apr; 26(2):113-20. PubMed ID: 22385406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series.
    Muñoz Ramos P; Gil Giraldo Y; Álvarez Chiva V; Quiroga B
    Medwave; 2021 Oct; 21(9):e8474. PubMed ID: 34669690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
    Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
    PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
    Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
    BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
    Covic A; Abraham I
    Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E; Demarteau N; Van Belle S; Annemans L
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.